Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: A multicenter randomized controlled trial
European Journal of Neurology, ISSN: 1351-5101, Vol: 20, Issue: 8, Page: 1161-1169
2013
- 60Citations
- 49Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations60
- Citation Indexes59
- 59
- CrossRef49
- Patent Family Citations1
- 1
- Captures49
- Readers49
- 49
Article Description
Background and purpose: We investigated the effect of celecoxib, a selective inhibitor of cyclo-oxygenase 2, in patients with intracerebral hemorrhage (ICH). Methods: We conducted a multicenter, randomized, controlled, and open with blinded end-point trial of 44 Korean patients 18years or older with ICH within 24h of onset. The intervention group (n=20) received celecoxib (400mg twice a day) for 14days. The control group (n=24) received the standard medical treatment for ICH. The primary end-point was the number of patients with a change in the volume of perihematomal edema (PHE) from the 1st to the 7th±1day (cut-off value, 20%). Results: The time from onset to computed tomography scan slightly differed between groups (177±160min for control vs. 297±305min for the celecoxib group; P=0.10). In the primary end-point analysis using cut-off values, there was a significant shift to reduced expansion of PHE in the celecoxib group (P=0.005). With respect to the secondary end-points, there was also a significant shift to reduced expansion of ICH in the celecoxib group (P=0.046). In addition, the expansion rate of PHE at follow-up tended to be higher in the control group than in the celecoxib group (90.6±91.7% vs. 44.4±64.9%; P=0.058). Conclusions: In our small, pilot trial, administration of celecoxib in the acute stage of ICH was associated with a smaller expansion of PHE than that observed in controls. © 2013 The Author(s) European Journal of Neurology © 2013 EFNS.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know